- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 46
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypogonadism
- Interventions
- QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C
- Drug
- Lead sponsor
- Antares Pharma Inc.
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- Metastatic Breast Cancer
- Interventions
- Anakinra plus Standard of Care
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo, Standard of Care
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 16
- States / cities
- Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more
- Conditions
- Leukemia
- Interventions
- Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2963016, LANTUS®, Oral Antihyperglycemic Medication
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- IPP-201101, Placebo, Standard of Care
- Drug · Other
- Lead sponsor
- ImmuPharma
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Leandro, California • Denver, Colorado + 6 more
- Conditions
- Literacy, Communication, Nonverbal
- Interventions
- ALLSTAR
- Behavioral
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- State College, Pennsylvania
- Conditions
- Hypertension
- Interventions
- Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 74
- States / cities
- Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Dasiglucagon, Standard of Care
- Drug · Other
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
- Procedure · Drug · Dietary Supplement + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 225
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Brenipatide, Placebo, Standard of Care
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Newport Beach, California • San Diego, California + 15 more
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
- Interventions
- STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin
- Drug
- Lead sponsor
- Synthekine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Beverly Hills, California • Fullerton, California + 26 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
- Conditions
- Thalassemia, Sickle Cell Disease, Healthy Controls
- Interventions
- Hydroxyurea, Acetazolamide
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Systemic Sclerosis With and Without Interstitial Lung Disease
- Interventions
- MK-2225, Placebo
- Biological
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 11
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- AMI
- Interventions
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Plasma Cell Disorder
- Interventions
- Daratumumab Injection
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Medication Adherence
- Interventions
- Screening and Brief Intervention (BI), Pill Box (PB)
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,091 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Marietta, Georgia • Pittsburgh, Pennsylvania
- Conditions
- Cystic Fibrosis
- Interventions
- Supportive Care Intervention
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
- Interventions
- Pegylated Interferon alpha-2b, Capecitabine, 5-FU
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Sleep, Diabetes Mellitus, Type 2
- Interventions
- Extended Sleep Intervention
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Lafayette, Colorado
- Conditions
- Smoking Cessation
- Interventions
- Standard Care (SC), Intensive Counseling (IC)
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York